Sarcopenia Predicts Outcome After Chemoimmunotherapy, Not Chemotherapy, in Advanced Lung Cancer: Single-Centre Retrospective Study - PubMed
8 hours ago
- #sarcopenia
- #predictive biomarker
- #chemoimmunotherapy
- Sarcopenia was prevalent in 49.5% of advanced NSCLC patients and associated with worse overall survival in the overall cohort.
- Sarcopenia significantly predicted poorer progression-free survival and overall survival in patients receiving chemoimmunotherapy (CITx), but not in those receiving chemotherapy alone (CTx).
- The interaction between sarcopenia and treatment type was statistically significant, indicating sarcopenia is a predictive biomarker specifically for inferior outcomes with CITx.
- Assessment of skeletal muscle mass may help identify patients at risk for suboptimal response to chemoimmunotherapy, suggesting a potential role for sarcopenia-targeted interventions.